Can GLP‑1 receptor agonists cause gallstones?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonists and Gallstone Risk

Yes, GLP-1 receptor agonists are associated with an increased risk of gallstones (cholelithiasis) and gallbladder disease, with the risk being dose-dependent and more pronounced with higher doses, longer duration of use, and when used for weight loss.

Evidence from Major Trials and Guidelines

The LEADER trial (liraglutide) demonstrated significantly more episodes of gallstone disease compared with placebo (145 vs. 90 episodes, P<0.001) 1. This finding has been consistently replicated across multiple systematic reviews and meta-analyses.

The most comprehensive meta-analysis of 76 randomized controlled trials involving 103,371 patients found that GLP-1 receptor agonists increased the risk of:

  • Gallbladder or biliary diseases overall (RR 1.37,95% CI 1.23-1.52)
  • Cholelithiasis specifically (RR 1.27,95% CI 1.10-1.47)
  • Cholecystitis (RR 1.36,95% CI 1.14-1.62)
  • Biliary disease (RR 1.55,95% CI 1.08-2.22) 2

A 2025 meta-analysis confirmed these findings, showing GLP-1 receptor agonists increased cholelithiasis risk (RR 1.46,95% CI 1.09-1.97), translating to 2 additional cases per 1,000 patients treated 3.

Risk Factors That Amplify Gallstone Formation

The risk is not uniform across all patients. Key risk amplifiers include:

  • Higher doses: RR 1.56 (95% CI 1.36-1.78) for higher doses vs. RR 0.99 (95% CI 0.73-1.33) for lower doses (P=0.006 for interaction) 2
  • Longer duration of use: RR 1.40 (95% CI 1.26-1.56) for longer duration vs. RR 0.79 (95% CI 0.48-1.31) for shorter duration (P=0.03 for interaction) 2
  • Weight loss indication: RR 2.29 (95% CI 1.64-3.18) when used for weight loss vs. RR 1.27 (95% CI 1.14-1.43) for diabetes management (P<0.001 for interaction) 2

Mechanism of Gallstone Formation

GLP-1 receptor agonists promote gallstone formation through multiple mechanisms 4:

  • Suppression of cholecystokinin, reducing gallbladder contractility
  • Delayed gastric emptying leading to bile stasis
  • Alterations in bile acid receptor signaling
  • Changes in gut-brain pathways affecting biliary function

The rapid weight loss induced by these medications further concentrates bile and increases lithogenic potential.

Clinical Guidance from Major Guidelines

The 2022 AGA Clinical Practice Guideline explicitly states that both semaglutide 2.4 mg and liraglutide 3.0 mg "have been associated with increased risk of pancreatitis and gallbladder disease" 5. Similarly, the 2025 guideline notes that tirzepatide "increases the risk of gallbladder or biliary disease in patients with T2DM and obesity," and emphasizes that "all GLP-1 RAs increase the risk of gallbladder or biliary disease" 6.

Practical Management Approach

When prescribing GLP-1 receptor agonists:

  1. Pre-treatment counseling: Inform patients about the 27-46% increased risk of gallstones, particularly if using higher doses or for weight loss
  2. Monitor for symptoms: Educate patients to report right upper quadrant pain, nausea after fatty meals, or jaundice
  3. Consider baseline risk: Patients with obesity undergoing rapid weight loss face compounded risk
  4. Dose titration: Gradual dose escalation may help mitigate gastrointestinal adverse effects but does not eliminate gallstone risk 5

Important Caveats

Despite the increased risk, the absolute number of additional cases remains relatively small (2 per 1,000 patients) 3. The cardiovascular, renal, and metabolic benefits of GLP-1 receptor agonists often outweigh this risk for appropriate patients 7, 5. However, this risk-benefit calculation should be explicitly discussed during shared decision-making, particularly for patients using these medications primarily for weight loss rather than diabetes management.

The Italian Society of Gastroenterology position paper confirms that while GLP-1 receptor agonists increase cholelithiasis risk, they are not associated with severe gastrointestinal complications or acute pancreatitis 8, providing reassurance about overall gastrointestinal safety despite the gallstone concern.

References

1
Guideline

clinical and investigative endocrinology and diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2018

8
Research

Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026

Related Questions

During which phase of treatment with GLP‑1 receptor agonists does gallstone formation occur—early (within the first few months) or later?
How should glucagon‑like peptide‑1 (GLP‑1) receptor agonist therapy be initiated and monitored in a patient with a prior history of gallstones?
What gallbladder-related symptoms can occur with glucagon‑like peptide‑1 (GLP‑1) receptor agonist therapy?
How should diarrhea caused by glucagon-like peptide‑1 (GLP‑1) receptor agonist therapy be managed?
Can glucagon‑like peptide‑1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide) worsen pre‑existing gallstones?
What is the incidence of constipation in patients receiving morphine?
What is KAL cream and how is it used to treat neuropathic pruritus?
Why does diuresis occur after initiating prednisolone therapy in nephrotic syndrome?
If a patient with Alzheimer’s disease was started on Donepezil prematurely and the initial cognitive concerns have resolved, should the medication be discontinued or continued?
Is a higher dose of ibuprofen required to reduce edema?
What surveillance schedule should be used for adult patients with gastric intestinal metaplasia, considering the extent of metaplasia and presence of dysplasia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.